ライフサイエンスコーパス: treated group

1 Quality of life was worse for the treated group.

2 vascular density was also reduced in the C4-treated group.

3 educed I/R injury as compared to the vehicle-treated group.

4 e prognosis in this bortezomib-dexamethasone-treated group.

5 al: 1.24-11.67, P = .0194) in the tamsulosin-treated group.

6 rable to or better than those of the vaccine-treated group.

7 -treated group compared with the IgG control-treated group.

8 p, and 0.91 (95% CI, 0.43-1.95) for the CPAP-treated group.

9 bacteria compared with BAL from the placebo-treated group.

10 hypoperfusion was reduced in the cilostazol-treated group.

11 art rate during exercise than in the placebo-treated group.

12 tment group and 82% (9/11) in the prednisone-treated group.

13 4 +/- 6%; p<0.05) compared to control premiR treated group.

14 ia, shoulder dystocia, and macrosomia in the treated group.

15 s hook use was similar in the two tamsulosin treated group.

16 CD8(+) T cells) was observed in the anti-B7h-treated group.

17 7, 10, 14, and 21 days than the DOX-beta-TCP-treated group.

18 tion parameters when compared to the vehicle-treated group.

19 was significantly less common in the statin-treated group.

20 in 1 mg MIA treated animals than in the 2 mg treated group.

21 ntly improved in Spirulina than in Silymarin treated group.

22 ere improved over the targeting polymer only treated group.

23 eated group than in the vehicle- or GW501516-treated group.

24 I male infertility compared with the vehicle-treated group.

25 with hypertrophy as observed in the vehicle-treated group.

26 L-27-treated group compared with the control-treated group.

27 dative stress damage as those in the vehicle-treated group.

28 treated group and 40 children in the placebo-treated group.

29 rneal infiltration compared with the vehicle-treated group.

30 resented results similar to those of the non-treated group.

31 in the anti-VEGF, but not anti-alpha4beta1, treated group.

32 ster and higher than the 20% in the siBmAce1-treated group.

33 s markers was also increased in the ketamine-treated group.

34 d to the recipients; and (iii) recipient ALA-treated group.

35 9 +/- 2.40 and 0.14 +/- 0.11 in the non-CA4P-treated group.

36 th stretch were similar to the non-TGF-beta1-treated group.

37 nated from the study sooner than either drug treated group.

38 4 h, whereas 6 of 9 rats survived in the DHA-treated group.

39 n-treated group compared with the FIV(+)/PBS-treated group.

40 ve reinnervation, compared with the dressing-treated group.

41 e tolerance between roflumilast- and placebo-treated groups.

42 gag and in gp41-CD in both the PI- and NNRTI-treated groups.

43 There was no bone loss in any treated groups.

44 ce rate between the surgically and medically treated groups.

45 ely to be 20/40 or better in the ranibizumab-treated groups.

46 ilar in the rivaroxaban-treated and warfarin-treated groups.

47 p<0.05) compared to respective control siRNA treated groups.

48 eated groups (CP-P+CYC) versus the CYC alone-treated groups.

49 exhibit statistical difference from the non-treated groups.

50 ia, granuloma, or collagen deposition in the treated groups.

51 ence of protection from immune attack in the treated groups.

52 s much reduced or absent in the 1 mg or sham treated groups.

53 up to 12 weeks after infarction between cell-treated groups.

54 e comparable between the SC and IV abatacept-treated groups.

55 ertrophied fibers from vehicle and tamoxifen-treated groups.

56 similar frequency in BMS-790052- and placebo-treated groups.

57 and ocular disease rebounded in prednisolone-treated groups.

58 erleukin-6 between vancomycin- and linezolid-treated groups.

59 fference in CNV between the AZM- and vehicle-treated groups.

60 s, with a dose-dependent increase in rhGDF-5-treated groups.

61 xcitability compared with untreated and sham-treated groups.

62 d complete remission was observed in the aFP-treated groups.

63 of CD8+ T cells to Treg increased in the aFP-treated groups.

64 ta-cells compared with corresponding vehicle-treated groups.

65 bserved after 10 months of treatment in both treated groups.

66 also were significantly lower in the CD47mAb-treated groups.

67 between sirolimus-treated and non-sirolimus-treated groups.

68 scular flow were compared between ultrasound-treated groups.

69 ignificantly (p < 0.05) reduced in the xenon-treated groups.

70 nfirmed ME cases were observed in fingolimod-treated groups (0.5 mg: n = 4, 0.3%; 1.25 mg: n = 15, 1.

71 Four hundred patients were treated (Group 1: 201, Group 2: 199).

72 nction (p < 0.05) were observed in the xenon-treated group, 1 month after trauma.

73 e Shannon's alpha-diversity was lower in the treated group (10.60; 95% CI, 8.82-12.36) than the place

74 re positive versus the number in the INP0341-treated group, 100% (25/25) and 31% (8/26), respectively

75 % lower Salmonella carriage is measured in a treated group, 14 days post-Salmonella challenge.

76 In 289 patients in the as-treated group (151 the HM3 and 138 the HMII), survival f

77 -1620 (24.47+/-4.37mm(3)) versus the vehicle-treated group (153.23+/-32.18mm(3)).

78 INA control group was similar for the MARINA treated group (+17.6 letters) and the FRB-MARINA cohort

79 survival for the overall cohort (hypothermia-treated group, 17.0% [246 of 1443 patients]; non-hypothe

80 number of SAEs per patient was higher in the treated group (2.7 versus 1.3; P = 0.003).

81 olyp scores after 16 weeks in the omalizumab-treated group (-2.67, P = .001), which was confirmed by

82 7.0% [246 of 1443 patients]; non-hypothermia-treated group, 20.5% [725 of 3529 patients]; RR, 0.79 [9

83 ere significantly increased (p<0.001) in the treated group (25.84+/-1.41%) compared with the control

84 In the treated group, 25(OH)D(total) rose from 18 +/- 7 to 43 +

85 ated for 4 wk (mean change in both sorafenib-treated groups, -38.4%; range, +9.1% to -79.4%).

86 ix days (8.8 +/- 0.4) compared to the saline-treated group (6.1 +/- 0.3; P < 0.001) without a change

87 s of any grade were higher in the duloxetine-treated group (78% v 50%); rates of grade 3 adverse even

88 Patients were split into 2 groups: not treated (group A, n = 312) and treated (group B, n = 361

89 ated tumors grew significantly slower in aFP-treated groups (aFP and aFP + anti-PD-1 groups) and comp

90 In clodronate-liposome-treated group, allograft hearts exhibited preserved tiss

91 and VF parameters tended to be worse in the treated group, although without statistical significance

92 .2-1.5; 11 of 3633 patients) in the edoxaban-treated group and 0.4% (0.2-1.7; 14 of 3594) in the warf

93 .2-0.5; 11 of 3633 patients) in the edoxaban-treated group and 0.7% (0.4-1.0; 24 of 3594 patients) in

94 5.63 +/- 3.09 and 1.68 +/- 0.77 in the CA4P-treated group and 1.29 +/- 2.40 and 0.14 +/- 0.11 in the

95 For vitamin E, there were 197 cases in the treated group and 192 in the placebo group (hazard ratio

96 One eye in the treated group and 2 eyes in the control group had an IOP

97 3-4.6; 143 of 3633 patients) in the edoxaban-treated group and 4.1% (3.5-4.8; 147 of 3594 patients) i

98 -60 months were analyzed in the azithromycin-treated group and 40 children in the placebo-treated gro

99 and 4.2%, respectively, in the SC abatacept-treated group and 65.2% and 4.9%, respectively, in the I

100 rgery-related complications was 8.61% in the treated group and 8% in the control group (not significa

101 oduct Statistics, we identified a dabigatran-treated group and a 1:2 propensity-matched warfarin-trea

102 and 26, respectively, in the 3 babies in the treated group and at week 19 in the baby in the control

103 h DMO was euro777.09 +/- 49.45 for the laser treated group and euro7153.62 +/- 212.15 for the anti-VE

104 sthenia developed in 8 of 76 patients in the treated group and in 15 of 82 patients in the nonimmunot

105 survival fivefold compared with the control-treated group and twofold compared with either two-drug

106 -/-)mice, compared, respectively, to vehicle-treated group and wild-type littermates.

107 ces in CAIX expression between the sorafenib-treated groups and the nontreated patients.

108 genes were found common to both 1,25(OH)2D3-treated groups and were composed of genes previously lin

109 ROP and treatment with laser or cryotherapy (treated group) and those with regressed ROP who had not

110 group, 0.93 (CI, 0.46 to 1.89) for the CPAP-treated group, and 1.38 (CI, 0.73 to 2.64) for the untre

111 a1-blockers before cataract surgery were the treated group, and age-, sex-, and year of surgery-match

112 study, FEV(1) was maintained in the original treated group, and improved in the original control grou

113 ) in the hippocampus and striatum of vehicle-treated group as compared to sham-operated rats.

114 GSH contents increased 44% in treated group as compared to the injury group.

115 s was significantly lower in the simvastatin-treated group, as was the urine albumin-creatinine ratio

116 and its effects were compared with a saline-treated group at five different time points of reperfusi

117 comparable in both vancomycin- and linezolid-treated groups at all three time points.

118 2 groups: not treated (group A, n = 312) and treated (group B, n = 361).

119 In both sorafenib-treated groups, baseline and posttreatment tumor targeti

120 s 1.2% (0.9-1.6; 51 of 4122) in the warfarin-treated group; between greater than 3 months and 6 month

121 pression and vessel density in the sorafenib-treated groups but no differences in CAIX expression bet

122 of PDGF-BB and VEGF were higher in the PRGF-treated group, but differences were not significant.

123 Functional outcome in 3K3A-APC-treated group, but not in vehicle-treated group, correla

124 The radiolabeled antibody-treated group (c) gave a median survival of 39 days, whi

125 rease of acute tubular injury in the CD47mAb-treated group compared to control.

126 PSA, and total cholesterol in the isoflavone-treated group compared to men receiving placebo were not

127 ng the formalin interphase period in the CRH-treated group compared to saline control groups; however

128 he crush, more neurons survived in the rtACS-treated group compared to sham-treated controls.

129 counts were consistently found in the saline-treated group compared with chlorhexidine (P = 0.03).

130 days after injections was 24% longer in ADF-treated group compared with controls (488 +/- 120 versus

131 -term corneal allograft survival in the IL-2 treated group compared with controls.

132 III IFNs in the airways (for the fluticasone-treated group compared with controls: mean IFNbeta BAL p

133 d eosinophilic inflammation in the abatacept-treated group compared with placebo (17.71% +/- 17.25% v

134 n major adverse cardiac events in the statin-treated group compared with placebo, yet no effect on an

135 were significantly decreased in the CD47mAb-treated group compared with the control group.

136 L-17 were significantly reduced in the IL-27-treated group compared with the control-treated group.

137 ippocampus were higher in the FIV(+)/insulin-treated group compared with the FIV(+)/PBS-treated group

138 s model was significantly reduced in the mAb-treated group compared with the IgG control-treated grou

139 were also reduced significantly in the 3CPI-treated group compared with these measures in the contro

140 cell density was significantly lower in ABX treated groups compared to controls.

141 apy, sIgE was significantly decreased in the treated groups compared to sham (P < 0.001), whereas sIg

142 ion incidence was lower in the combined cell-treated groups compared with control group (6 months: P=

143 for threat information was decreased in the treated group, compared with the waiting group, the day

144 nt (ADC) measured by DW-MRI increased in the treated group consistent with cytotoxic edema.

145 sitive, whereas only 5.1% in the doxycycline-treated group contained bacteria.

146 n 3K3A-APC-treated group, but not in vehicle-treated group, correlated inversely with the reductions

147 amin E and C levels were high in combination-treated groups (CP-P+CYC) versus the CYC alone-treated g

148 The ACE inhibitor-treated group demonstrated a significant reduction in sy

149 in periocular inflammation, the radiotherapy-treated group demonstrated a significantly greater impro

150 Skin cells from the contrast-treated group demonstrated greater hPAP expression with

151 FA-treated groups demonstrated significantly fewer activate

152 The cell-treated group displayed a significant increase in vascul

153 The ketamine-treated group displayed bladder hyperactivity and decrea

154 Surviving rats in the DHA-treated group displayed moderately improved hemodynamics

155 myogenic differentiation in pre-culture SBB-treated groups do not exhibit statistical difference fro

156 8-OHdG concentrations was found in all three treated groups during 3-month (P<0.001) and 6-month (P<0

157 Only the UC-MSC-treated group exhibited significant improvements in left

158 The treated groups exhibited dose-dependent hypophosphatemia

159 randomized to either Spirulina or Silymarin treated groups for a period of six months treatment.The

160 The tumors in the mP-PTX treated group grew more slowly than those treated with s

161 n the intention-to-treat analysis, the CLEAR-treated group had a mean (SD) decrease in lesion diamete

162 The treated group had a mean improvement in FEV(1) of 105 ml

163 The treated group had a relative improvement in FEV(1) of 3.

164 After 12 wk, the treated group had a significantly better total SPPB scor

165 Patients in the treated group had a significantly thinner choroidal thic

166 gn of brain function whereas rats in the DHA-treated group had recurrent seizures and spontaneous res

167 Histologically the CD47mAb-treated group had significantly reduced scores of acute

168 However, MyMRKO and EPL-treated groups had a 35% reduction in serum cystatin-C l

169 AgNS and AgNC treated groups had select reductions in gut microbiota r

170 val in the PGD3-cohort was 71.4%, the C1-INH-treated-group had a one-year-survival of 82.5%, the cont

171 rates were low, but there were fewer in the treated group (hazard ratio, 0.74; 95% confidence interv

172 closure group versus 10.2% in the medically treated group; hazard ratio, 0.64; 95% confidence interv

173 In the treated groups, hearts were perfused with ranolazine or

174 .4-1.0; 24 of 3594 patients) in the warfarin-treated group (HR 0.45, 95% CI 0.22-0.92).

175 d 0.4% (0.2-1.7; 14 of 3594) in the warfarin-treated group (HR 0.78, 95% CI 0.36-1.72).

176 5-4.8; 147 of 3594 patients) in the warfarin-treated group (HR 0.97, 95% CI 0.77-1.22); cumulative in

177 were rates of hypertension in the olanzapine treated group (HR 1.41, 95% CI 1.06-1.87; p = 0.017).

178 1).day(-1)) in the supplied water (infarcted treated group, I + PY).

179 multinucleated cells were observed in the EA-treated group in relation to group EP.

180 overy from stroke, compared with the vehicle-treated groups in a 12h permanent middle cerebral artery

181 nce was found between sham-TBI and PGI-02776 treated groups in either analysis indicating an improvem

182 differences between bortezomib- and placebo-treated groups in median measured GFR at 24 months (33 v

183 ere significantly (p < 0.05) better in xenon-treated groups in the early phase (24 hr) and up to 4 da

184 ascular events remained consistent in the TO-treated groups in the PCI and CABG arms.

185 red and not treated), and tiotropium bromide-treated groups, including both preinjury and postinjury

186 ogical examination of the lenses in the NACA-treated group indicated that NACA was able to reverse th

187 -PGC-1alpha was decreased in the resveratrol-treated group, indicating a higher level of activation,

188 on-targets was significantly enhanced in the treated group, indicating memantine-associated improveme

189 ut microbiome was significantly lower in the treated group (inverse Simpson's alpha-diversity, 5.03;

190 In the metformin-treated group, Ki-67 was 12.9% lower at hysterectomy tha

191 symptoms of infectious disease while the Pn treated group looked healthy.

192 In the as-treated group (n = 124), clinical (P = .003) and radiolo

193 icantly higher (P = .001) in the canakinumab-treated group (n = 5 of 7) than in the placebo group (n

194 injured group (n = 5), an injured and saline-treated group (n = 6), or an injured group treated with

195 In the as-treated group, natalizumab continuers received natalizum

196 In the vehicle-treated groups, no significant change in TBR, K1, K1/k2,

197 group and a 1:2 propensity-matched warfarin-treated group of 4,978 and 8,936, respectively.

198 7 and 16 postinfection in the immunocomplex-treated group of infected mice.

199 s (miR) could segregate a largely surgically treated group of mesotheliomas into good or bad prognosi

200 ll numbers in corneas from the immunocomplex-treated group of mice.

201 outcome in our study is comparable to the IA-treated group of the MR CLEAN trial and better than the

202 Two orthodontically treated groups of 35 patients each, with (Cort) and with

203 We treated groups of animals with 1 dose of VSV-EBOV either

204 nalyses were undertaken in the TO and non-TO treated groups of both study arms.

205 We treated groups of nude mice bearing 7-d-old SW1222 xenog

206 .04) 3 months after PTRA in the elamipretide-treated group only.

207 In the etidronate-treated group, OPG expression was significantly expresse

208 least one minor (C) allele in the bupropion-treated group (OR=0.43; 95% CI=0.22-0.77; P=0.005) but e

209 rs post-MCAO with either 1 mg/kg PNU-120596 (treated group) or vehicle only (untreated group).

210 aled mannitol, 400 mg twice a day (n = 192, "treated" group) or 50 mg twice a day (n = 126, "control"

211 ed in the sirolimus-treated vs non-sirolimus-treated groups overall (26 of 97 [26.8%] vs 89 of 232 [3

212 Within the ICS-treated groups, OW and NW children had similar asthma sy

213 h sTNF-RII, particularly in the chemotherapy-treated group (P < .05).

214 ons, which were lower in the cholecalciferol-treated group (P < 0.04).

215 ated in the gingival tissue of the 10 mug/kg treated group (p < 0.05).

216 % CI, 1.9-14.9) higher than the voriconazole-treated group (P = .01).

217 er probability of survival in the daptomycin-treated group (P = .022).

218 than study participants in the voriconazole-treated group (P = .046).

219 an increase of 0.07 (3.2) mm in the placebo-treated group (P = .05).

220 reak point the slope became shallower in the treated group (P = 0.002).

221 .22-mm radius decreased significantly in the treated group (P = 0.005).

222 he radiolabeled antibody-conjugated liposome-treated group (P = 0.5).

223 s than that of 2.5 and 10 mg/kg cyclosporine-treated groups (p < .05).

224 ue thickness gain was significant only in CM-treated groups (P <0.05).

225 vs. recombinant tissue plasminogen activator-treated groups (p=.03 and p=.08, respectively).

226 up did not improve in either groups (p = 0.8 treated group, p = 0.1 control group).

227 e found by either quadrant analysis (p = 0.1 treated group, p = 0.5 control group) or MD analysis (p

228 0.5 control group) or MD analysis (p = 0.2, treated group, p = 0.9 control group).

229 In contrast to controls, the chemotherapy-treated group performed significantly worse on attention

230 was higher than placebo in both of the cell-treated groups (placebo vs. CDC, p = 0.01; placebo vs. c

231 dication scores improved in both Bet v 1 COP-treated groups, reaching statistical significance over p

232 All treated groups received an additional 14.4 mug every 4 h

233 rol group was given a normal diet, while the treated groups received the same diet with oral suppleme

234 showed a significant improvement in the NgR-treated group relative to the control group (p < 0.005,

235 -octreotate group, and the (177)Lu-DOTA-JR11-treated group, respectively.

236 for ALT and AST, in Vit D, LE and LE + Vit D treated groups, respectively).

237 Los and Tel treated group resulted in the 5.33 and 14.33 fold increa

238 The DOX-beta-TCP + EDTA-treated group retained more DOX during the periods of 3,

239 DOX-COL + EDTA-treated group retained more DOX during the periods of 3,

240 HS-treated groups revealed persistent scar tissue for 10 we

241 tacle-corrected visual acuity, the natamycin-treated group scored 8.4 points (95% CI, 1.9-14.9) highe

242 und that study participants in the natamycin-treated group scored, on average, 4.3 points (95% CI, 0.

243 At 21 days, the DOX-beta-TCP + EDTA-treated group showed a 194.7 microg/mL value.

244 Overall, FIR-treated group showed a higher DPPH radical scavenging ac

245 ontrol group, corneas from the immunocomplex-treated group showed a significant reduction in the amou

246 The prednisone-treated group showed an adjusted mean 6.4-point (95% CI,

247 The IL-10-treated group showed increased retention of transplanted

248 r mouse model, MDB5 containing nanoparticles treated group showed significant inhibition of tumor gro

249 The ozone-treated group showed significantly higher quality of lif

250 Concurrently, the treated group showed visible lesions, a higher FDG uptak

251 Control and treated groups showed 41 and 29 common species among the

252 to their respective controls, all three drug-treated groups showed robust seizure-like responses (hyp

253 In the dermis and subcutaneous fat, the EVE treated groups showed significant increases in blood ves

254 abolic tissues tested in vehicle- or BRD3308-treated groups showed virtually no sign of immune cell i

255 opine and control groups, with both atropine-treated groups showing significant myopic retardation co

256 une responses in the two vaccinated and mock treated groups, similar quantities of viral RNA were det

257 Compared with the placebo and rBet v 1-treated groups, SLIT with rMal d 1 reduced rMal d 1-indu

258 a control group (CG; n = 60) and a meloxicam-treated group (TG; n = 60) that received either a single

259 s were less pronounced in hearts in the cell-treated group than in MI hearts (P<0.05), and these impr

260 GF expression were more prevalent in the CsA-treated group than in the control group (P <0.05).

261 icantly less muscle fiber injury in the PJ34-treated group than in the Lactated Ringer-treated mice a

262 ore was 1.2 points higher in the simvastatin-treated group than in the placebo group (95% CI 0.2-2.3)

263 t) were all significantly higher in the NACA-treated group than in the sodium selenite-induced catara

264 ular matrix proteins was lower in the KD3010-treated group than in the vehicle- or GW501516-treated g

265 at 80 MPa after vitrification-warming in the treated groups than controls.

266 eral density and bone volume fraction in PTH-treated groups than in controls.

267 amylase activity was significantly higher in treated groups than in controls.

268 activity was significantly lower in the PJ34-treated groups than in the Lactated Ringer group at 7 an

269 Relative to the VKA-treated group, the associated risk of MI was significant

270 In the siRNA-treated group, the expression of 32-kDa caspase-3 precur

271 In contrast to the vehicle-treated group, the hippocampus of animals receiving RESV

272 one revealed that, compared with the vehicle-treated group, the PTH-treated WT mice had reduced trabe

273 s showed increases especially at the 100% N2-treated group, the total FAAs statistically differed wit

274 Further, in Tel and Los treated groups, the TGF-beta1 active levels were signifi

275 appeared least at end of storage for 100% N2 treated-group, the latter having decreased melanosis sco

276 2 in the moderate- and high-intensity statin-treated groups; the LDL-C reductions at week 12 were com

277 re was well preserved, whereas in the saline-treated group, tubular injury was severe, with marked tu

278 ion in the course of a year, 41% of the IVIg-treated group underwent transplantation during the study

279 ion of NCe was found in tumors isolated from treated group using transmission electron microscopy (TE

280 .8-1.4; 44 of 4118 patients) in the edoxaban-treated group versus 1.2% (0.9-1.6; 51 of 4122) in the w

281 alysis indicated 0% of HBsAg+ infants in the treated group versus 2.84% in the NTx group (P=0.002).

282 ce [CI]: 0.6-3.8) of HBsAg+ infants from the treated group versus 7.6% (95% CI: 4.9-10.3) in the NTx

283 acebo; 78% DHA); the mean DHA intake for the treated group was 469 mg/d.

284 the forebrain white matter of the isoflurane-treated group was 6.3% of the total population of myelin

285 Severe TV observed in the non-treated group was associated with increased protein oxid

286 Dermal cellularity in the contrast-treated group was fourfold that of control.

287 Survival in the CT-1-treated group was higher than in the untreated group and

288 uramine-induced serotonin/prolactin in the T-treated group was significantly higher than the other gr

289 The surgically treated group was the only group with clinically signifi

290 Viral RNA from the HCV sshRNA-treated groups was altered in sequences complementary to

291 In the chemotherapy-treated group, we found significant decreases of FA in f

292 filtration of CD8(+) T-cells in the polyplex treated group were improved over the targeting polymer o

293 ol group, but not in the NF-kappaB inhibitor-treated groups, whereas TAT levels were elevated in all

294 obtained in the adhesive tissues of the APC-treated group, which correlated with significantly reduc

295 This pattern was reversed in the AL-treated groups, which displayed a decrease in blood vess

296 f treatment weighting to create DES- and BMS-treated groups whose observed baseline characteristics w

297 onditions or groups (e.g. a control and drug-treated group) with the goal of identifying discriminato

298 and 4.9%, respectively, in the IV abatacept-treated group, with comparable frequencies of serious in

299 d only within the anterior stroma of the UVA-treated groups, with no significant difference in the de

300 In addition, in the AI treated group znp-1 antibody staining of the primary mot